Shares of Aridis Pharmaceuticals Inc (NASDAQ:ARDS) have been given an average rating of “Buy” by the six ratings firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $28.25.
Several research analysts have weighed in on ARDS shares. Zacks Investment Research upgraded Aridis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a report on Tuesday, November 13th. Cantor Fitzgerald reiterated a “buy” rating and set a $25.00 target price on shares of Aridis Pharmaceuticals in a report on Tuesday, November 13th. Maxim Group set a $25.00 target price on Aridis Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, November 13th. Laidlaw started coverage on Aridis Pharmaceuticals in a report on Monday, September 10th. They set a “buy” rating and a $23.00 target price on the stock. Finally, Northcoast Research started coverage on Aridis Pharmaceuticals in a report on Monday, September 10th. They set an “outperform” rating and a $40.00 target price on the stock.
ARDS stock opened at $8.54 on Friday. Aridis Pharmaceuticals has a 1-year low of $7.59 and a 1-year high of $13.85.
Aridis Pharmaceuticals (NASDAQ:ARDS) last posted its earnings results on Tuesday, November 13th. The company reported ($1.97) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.05) by ($0.92). The business had revenue of $1.02 million during the quarter, compared to analysts’ expectations of $0.33 million. As a group, sell-side analysts anticipate that Aridis Pharmaceuticals will post -3.05 earnings per share for the current year.
About Aridis Pharmaceuticals
Aridis Pharmaceuticals, Inc engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-105, AR-101, AR-401, AR-201, and AR-501. The company was founded by Eric J. Patzer and Vu L.
Recommended Story: Hedge Funds
Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.